# Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

> **NCT04250051** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Northwestern University** · enrollment: 2 (actual)

## Conditions studied

- Recurrent Acute Myeloid Leukemia
- Recurrent Myelodysplastic Syndrome
- Recurrent Myeloproliferative Neoplasm
- Refractory Acute Myeloid Leukemia
- Refractory Myelodysplastic Syndrome

## Interventions

- **DRUG:** Cytarabine
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Fludarabine
- **DRUG:** Fludarabine Phosphate
- **DRUG:** Ivosidenib

## Key facts

- **NCT ID:** NCT04250051
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-21
- **Primary completion:** 2025-01-08
- **Final completion:** 2028-12-01
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2025-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04250051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04250051, "Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04250051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*